Resolving inflammation, broadly
6A Preston Court
Resolvyx Pharmaceuticals Inc.
Resolvyx Pharmaceuticals is developing a new class of lipid mediators, dubbed resolvins, which are generated through the oxidation of the omega-3 fatty acids EPA and DHA. Although omega-3 fatty acids have long been heralded for their reputed ability to reduce inflammation, many grams of omega-3 fatty acids have to be consumed to produce any physiological effect. In contrast, Resolvyx says its resolvins are potent at low milligram quantities and so are good candidates for commercialization as drugs. Resolvyx is advancing two programs into the clinic.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
• By
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
• By
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
• By
The quarter saw strong growth overall, but the company now expects sales of Yescarta and Tecartus to fall for the full year 2025 versus 2024 thanks to competition.
• By
Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.
• By
The accelerated approval came three months after Jazz completed the acquisition of Modeyso’s developer, Chimerix.